DBV TECHNOLOGIES SA-SPON ADR (DBVT) Stock Price & Overview
NASDAQ:DBVT • US23306J2006
Current stock price
The current stock price of DBVT is 21.06 USD. Today DBVT is up by 2.73%. In the past month the price decreased by -4.62%. In the past year, price increased by 224%.
DBVT Key Statistics
- Market Cap
- 1.157B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.64
- Dividend Yield
- N/A
DBVT Stock Performance
DBVT Stock Chart
DBVT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to DBVT. When comparing the yearly performance of all stocks, DBVT is one of the better performing stocks in the market, outperforming 96.43% of all stocks.
DBVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DBVT. DBVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DBVT Earnings
On March 26, 2026 DBVT reported an EPS of -0.5 and a revenue of 645.00K. The company missed EPS expectations (-107.02% surprise) and beat revenue expectations (4.35% surprise).
DBVT Forecast & Estimates
8 analysts have analysed DBVT and the average price target is 24.23 USD. This implies a price increase of 15.04% is expected in the next year compared to the current price of 21.06.
For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBVT
DBVT Groups
Sector & Classification
DBVT Financial Highlights
Over the last trailing twelve months DBVT reported a non-GAAP Earnings per Share(EPS) of -1.64. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.56% | ||
| ROE | -142.22% | ||
| Debt/Equity | 0.08 |
DBVT Ownership
DBVT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DBVT
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Company Info
IPO: 2012-03-29
DBV TECHNOLOGIES SA-SPON ADR
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES 92120 FR
CEO: Daniel Tasse
Employees: 109
Phone: 33155427878
DBV TECHNOLOGIES SA-SPON ADR / DBVT FAQ
Can you describe the business of DBV TECHNOLOGIES SA-SPON ADR?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
What is the current price of DBVT stock?
The current stock price of DBVT is 21.06 USD. The price increased by 2.73% in the last trading session.
Does DBVT stock pay dividends?
DBVT does not pay a dividend.
What is the ChartMill technical and fundamental rating of DBVT stock?
DBVT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is DBVT stock listed?
DBVT stock is listed on the Nasdaq exchange.
Should I buy DBVT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DBVT.
What is the expected growth for DBVT stock?
The Revenue of DBV TECHNOLOGIES SA-SPON ADR (DBVT) is expected to decline by -55.09% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.